MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies
2025-09-05
(Press-News.org)
Agreement focuses on rimiducid, an agent used to activate certain safety switch technologies in cell therapies
Phoenix receives a supply of rimiducid and support to seek regulatory approval of a new proprietary injectable formulation, retaining exclusive rights for use in its novel in vivo gene therapy programs
MD Anderson receives rights to the new formulation of rimiducid for use with its inducible switches exclusively in ex vivo cell therapies
Collaborators hope to use these tools to further enhance cell and gene therapies
HOUSTON and MIAMI, SEPTEMBER 5, 2025 ― The University of Texas MD Anderson Cancer Center and Phoenix SENOLYTIX, Inc., today announced a global cross-licensing agreement to facilitate work that will further enhance the development of inducible switch technologies for use in cell and gene therapies.
Under the terms of the agreement, Phoenix will receive a supply of rimiducid from MD Anderson and support for seeking regulatory approval of a new proprietary formulation that can be delivered via intramuscular or subcutaneous (IM/SC) injection as opposed to intravenous infusion. MD Anderson receives exclusive rights to Phoenix’s new formulation of rimiducid for use with its inducible switch technologies in its cell therapy platforms.
Rimiducid is a therapeutic agent used to activate inducible switch technologies, including the CaspaCIDe® (inducible caspase-9, iCasp9, or iC9) safety switch as well as GoCAR-T®, GoTCR®, GoDCVaX® and Dual Switch technologies acquired by MD Anderson from Bellicum Pharmaceuticals, Inc. The switches and rimiducid can be used as a safety feature to regulate the activity of cell and gene therapies.
“While we have had very promising safety results with our engineered cell therapies, it is critical that we include effective technologies to rapidly eliminate transduced cells in the event of treatment-related toxicities,” said Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy and vice president and head of the Institute for Cell Therapy Discovery & Innovation at MD Anderson. “We look forward to working with Phoenix to continue developing these important technologies to enhance our cell therapy programs.”
MD Anderson’s Institute for Cell Therapy Discovery & Innovation is focused on developing and advancing impactful cell therapy for patients in need. Its researchers have incorporated the CaspaCIDe safety switch into multiple cell therapy programs, including chimeric antigen receptor (CAR) natural killer (NK) cell therapies. The institution also has made the inducible switch technologies available via non-exclusive licenses to other academic institutions and biopharmaceutical companies.
The CaspaCIDe technology was originally developed by David Spencer, Ph.D., a co-founder of Phoenix who served as the scientific founder of Bellicum. Phoenix has now developed its proprietary ApoptiCIDe™ platform, an evolution of the original technology specifically designed to work with the new rimiducid formulation. The platform is capable of being incorporated into both cell and gene therapies, and Phoenix has utilized this technology for its lead products, which are designed to accomplish purposeful in vivo elimination of targeted cell populations in aging and obesity-related disorders.
“We are excited about the broad medical opportunities presented by the dimerizer applications that would be enhanced with this new formulation of rimiducid,” said Spencer, chief technology officer at Phoenix. “This reflects a potentially major advance that should further expand the adoption of cell and gene therapies.”
In addition to the cross-license agreement, Phoenix and MD Anderson have agreed to establish a scientific advisory board to inform the continued development of these products for MD Anderson’s cell therapy programs. Members from Phoenix will include Spencer, Daniel Jasinski, Ph.D., and Kevin Slawin, M.D., the founder of both Bellicum Pharmaceuticals and Phoenix SENOLYTIX. MD Anderson members will include Rezvani and two additional experts to be named.
- 30 -
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-09-05
Hydrogen is the most abundant element in the solar system. As a source of clean energy, hydrogen is well-suited for sustainable development, and Earth is a natural hydrogen factory. However, most hydrogen vents reported to date are small, and the geological processes responsible for hydrogen formation—as well as the quantities that can be preserved in geological settings—remain unclear.
To better understand the availability of geological hydrogen, researchers from the Institute of Oceanology of the Chinese Academy of Sciences (IOCAS) and their collaborators discovered and analyzed a large pipe swarm—a ...
2025-09-05
A new study from the University of North Carolina at Chapel Hill shows that insect populations are rapidly declining even in relatively undisturbed landscapes, raising concerns about the health of ecosystems that depend on them.
Keith Sockman, associate professor of biology at UNC-Chapel Hill, quantified the abundance of flying insects during 15 seasons between 2004 and 2024 on a subalpine meadow in Colorado, a site with 38 years of weather data and minimal direct human impact. He discovered an average annual decline of 6.6% in insect abundance, amounting to a ...
2025-09-05
Breaking free from spectral limits
From thermal cameras to multispectral sensors, modern surveillance technologies are increasingly difficult to evade, creating urgent demand for camouflage that adapts across both visible and infrared bands. Yet progress has long been constrained by three persistent challenges: the tight coupling between visible color shifts and infrared emissivity, which forces trade-offs; the limited thermal modulation range of existing devices, typically <15 °C and insufficient for extreme environments such as deserts with >60 °C swings; and scalability constraints, with most prototypes restricted ...
2025-09-05
MD Anderson Research Highlights for September 5, 2025
Clinical trials show promising results in treating pancreatic and colorectal cancers
New treatment strategies improve outcomes for patients with kidney and testicular cancers
Novel research techniques enable advances in gene-drug interactions, breast cancer progression, and identifying pre-cancerous lesions
Biomarkers help predict risk for oral cancer metastasis
HOUSTON, SEPTEMBER 5, 2025 ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research ...
2025-09-05
Imagine a clock that doesn’t have electricity, but its hands and gears spin on their own for all eternity.
In a new study, physicists at the University of Colorado Boulder have used liquid crystals, the same materials that are in your phone display, to create such a clock—or, at least, as close as humans can get to that idea. The team’s advancement is a new example of a “time crystal.” That’s the name for a curious phase of matter in which the pieces, such as atoms or other particles, exist in constant motion.
The researchers aren’t the first to make a time crystal, but their creation is the first that humans can actually ...
2025-09-05
The Europlanet Science Congress 2025 will be held jointly with the annual meeting of the American Astronomical Society’s Division of Planetary Science (EPSC-DPS2025) from 7–12 September 2025 at Finlandia Hall, Helsinki, Finland. With around 1800 participants expected to join in person and online, it will be the largest planetary science meeting held to date in Europe.
Press briefings will be livestreamed and press notices on presentations of interest to the media will be issued by the EPSC-DPS2025 ...
2025-09-05
Since their discovery at Drexel University in 2011, MXenes — a family of nanomaterials with unique properties of durability, conductivity and filtration, among many others — has become the largest known and fastest growing family of two-dimensional nanomaterials, with more than 50 unique MXene materials discovered to date. Experimentally synthesizing them and testing the physical properties of each material has been the labor of tens of thousands of scientists from more than 100 countries. But a recent discovery by a multi-university collaboration of researchers, led by Drexel University researcher Yury ...
2025-09-05
Chicago, IL — The JAMA Network announces the launch of JAMA+ Women’s Health, a new digital resource designed to elevate the visibility and accessibility of trusted, peer-reviewed content that advances health care for women across the globe.
Recognizing that women’s health is more comprehensive than reproductive care, gynecologic and breast cancer, and menopause, JAMA+ Women’s Health will showcase rigorous studies that include or focus exclusively on women from across JAMA and the 12 JAMA Network journals.
Linda Brubaker, MD, MS, the JAMA+ Women’s Health Editor in Chief, will curate the site.
“There’s ...
2025-09-05
Highly efficient controlling the individual atomic migration is the basis of the modern atomic manufacturing. Although one-by-one atom migration can be realized precisely by STM technique, such a delicate operation is time consuming and restrictive conditions (e.g., high-vacuum) is required.
A research team from the Institute of Modern Optics and the Center for Single Molecule Science at Nankai University, China, has now reported a breakthrough method to achieve efficient atomic migration under room temperature and atmospheric conditions. Their study, titled “Surface Plasmon Driven Atomic Migration Mediated by Molecular Monolayer,” was recently published in PhotoniX.
By ...
2025-09-05
Five researchers from the University of Groningen, the Netherlands, have been awarded an ERC Starting Grant. They are Michael Lerch, Loredana Protesescu, Tim Lichtenberg and Alexander Belyy from the Faculty of Science and Engineering, and Miles Wischnewski from the Faculty of Behavioural and Social Sciences.
The European Research Council's (ERC) Starting Grants amount to €1.5 million each, for a period of five years. The grants are intended for outstanding researchers with the aim of stimulating cutting-edge research in Europe.
Miles Wischnewski: The role of phase coding in memory processing
Imagine walking into a room ...
LAST 30 PRESS RELEASES:
[Press-News.org] MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies
